These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution].
    Author: Stoenescu TM, Ivan LD, Stoenescu N, Azoicăi D.
    Journal: Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):485-92. PubMed ID: 21870745.
    Abstract:
    In defining new potential prognostic factors in cervical cancer, p53 protein expression, Ki67 or issues related to Bcl-2 oncogene involved in cellular apoptosis process, have been the subject of numerous publications. This paper aims to study with immunohistochemical methods, the way in which these factors are involved in influencing the prognosis of patients with cervical cancer. The study was conducted on 42 pieces operators from the same number of patients diagnosed with this disease, aged between 25-65 years and in different clinical stages. We used an experimental design type 2 (histopathological type squamous cell/adenocarcinoma) x 3 (degree of differentiation weak/ moderate/ well differentiated) x 4 (stage I/ II/ III /IV disease). Diagnosis was based on clinical examination and confirmed by histopathology, and hypothesis testing we used Kruskal-Wallis ANOVA test of ranks test, Mann-Whitney U test, chi2 test, Spearman's correlation test and crosstabs ranking difference. The results on the study group showed the prognostic value of both the proliferation marker Ki67 and p53 oncogene, the presence of tandem Ki67/p53 in cervical carcinoma meaning more so a poor prognosis, Bcl-2 overexpression was detected in none of the 42 cases investigated.
    [Abstract] [Full Text] [Related] [New Search]